- Home
- / Werewolf Therapeutics
Werewolf Therapeutics
Stock Price
$2.2
2024-08-19
Market Capitalization
$94.8 M
2024-08-19
Werewolf Therapeutics Summary
Company Summary
- Overview
- Werewolf Therapeutics is an oncology biotherapeutics company that develops cancer treatments designed to focus the body’s immune response to selectively target cancer. Its products are used for the treatment of advanced solid tumors, relapsed or refractory advanced or metastatic solid tumors, lymphoma, and hematologic malignancies.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://werewolftx.com/
- Cybersecurity rating
Table of Contents
Key People
Cynthia Seidel-Dugan, Chief Scientific Officer
Reid Leonard, Chief Operating Officer
Randi Isaacs, Chief Medical Officer
Werewolf Therapeutics Financials
Summary Financials
- Net income (Q2, 2024)
- ($17.2M)
- Cash (Q2, 2024)
- $135.3M
- EBIT (Q2, 2024)
- ($19.0M)
- Enterprise value
- ($8.4M)